| pubmed-article:15074470 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15074470 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:15074470 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:15074470 | lifeskim:mentions | umls-concept:C0242957 | lld:lifeskim |
| pubmed-article:15074470 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:15074470 | lifeskim:mentions | umls-concept:C0027627 | lld:lifeskim |
| pubmed-article:15074470 | lifeskim:mentions | umls-concept:C1517050 | lld:lifeskim |
| pubmed-article:15074470 | pubmed:issue | 3-4 | lld:pubmed |
| pubmed-article:15074470 | pubmed:dateCreated | 2004-4-12 | lld:pubmed |
| pubmed-article:15074470 | pubmed:abstractText | We studied the serum HER-2 extracellular domain (sHER-2) before the first metastases in 128/701 breast cancer patients diagnosed and followed-up in our institution who developed metastases as the first relapse. sHER-2 was measured by an enzyme-linked immnunosorbent assay and CA 15.3 by an immunoradiometric assay. Non-parametric statistics were used. sHER-2 and CA 15.3 before and after primary treatment were measured in a previous part of the study. Before first metastases, 45% of the samples were over 12 microg/l of sHER-2 (cut-off) and were significantly related to sHER-2 values before and after primary treatment (P = 0.0350 and P < 0.0001 respectively). Concordance with CA 15.3 was 56.25 % (weak correlation, rho = 0.263). sHER-2 levels differed according to the sites of the metastases (P = 0.0199), the highest levels were found in liver and lung metastases. A median sHER-2 lead time of 254 days was found for 18/28 (64.3 %) patients before first metastasis. Pre-metastatic sHER-2 levels showed strong univariate (Kaplan-Meier method, P = 0.0014) and multivariate prognostic values (Cox model, P < 0.0001) for survival after first metastasis. In recurrent breast cancer, elevated levels of sHER-2 enabled an early detection of occult metastases and the identification of patients with a high probability of shortened survival. | lld:pubmed |
| pubmed-article:15074470 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15074470 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15074470 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15074470 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15074470 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15074470 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15074470 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15074470 | pubmed:issn | 1433-6510 | lld:pubmed |
| pubmed-article:15074470 | pubmed:author | pubmed-author:NeumannRainer... | lld:pubmed |
| pubmed-article:15074470 | pubmed:author | pubmed-author:HaceneKamelK | lld:pubmed |
| pubmed-article:15074470 | pubmed:author | pubmed-author:PichonMarie-F... | lld:pubmed |
| pubmed-article:15074470 | pubmed:author | pubmed-author:GuepratteSylv... | lld:pubmed |
| pubmed-article:15074470 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15074470 | pubmed:volume | 50 | lld:pubmed |
| pubmed-article:15074470 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15074470 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15074470 | pubmed:pagination | 163-70 | lld:pubmed |
| pubmed-article:15074470 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:15074470 | pubmed:meshHeading | pubmed-meshheading:15074470... | lld:pubmed |
| pubmed-article:15074470 | pubmed:meshHeading | pubmed-meshheading:15074470... | lld:pubmed |
| pubmed-article:15074470 | pubmed:meshHeading | pubmed-meshheading:15074470... | lld:pubmed |
| pubmed-article:15074470 | pubmed:meshHeading | pubmed-meshheading:15074470... | lld:pubmed |
| pubmed-article:15074470 | pubmed:meshHeading | pubmed-meshheading:15074470... | lld:pubmed |
| pubmed-article:15074470 | pubmed:meshHeading | pubmed-meshheading:15074470... | lld:pubmed |
| pubmed-article:15074470 | pubmed:meshHeading | pubmed-meshheading:15074470... | lld:pubmed |
| pubmed-article:15074470 | pubmed:meshHeading | pubmed-meshheading:15074470... | lld:pubmed |
| pubmed-article:15074470 | pubmed:meshHeading | pubmed-meshheading:15074470... | lld:pubmed |
| pubmed-article:15074470 | pubmed:meshHeading | pubmed-meshheading:15074470... | lld:pubmed |
| pubmed-article:15074470 | pubmed:meshHeading | pubmed-meshheading:15074470... | lld:pubmed |
| pubmed-article:15074470 | pubmed:meshHeading | pubmed-meshheading:15074470... | lld:pubmed |
| pubmed-article:15074470 | pubmed:meshHeading | pubmed-meshheading:15074470... | lld:pubmed |
| pubmed-article:15074470 | pubmed:meshHeading | pubmed-meshheading:15074470... | lld:pubmed |
| pubmed-article:15074470 | pubmed:meshHeading | pubmed-meshheading:15074470... | lld:pubmed |
| pubmed-article:15074470 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15074470 | pubmed:articleTitle | Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients. | lld:pubmed |
| pubmed-article:15074470 | pubmed:affiliation | Laboratoire d'Oncobiologie, Centre René Huguenin Saint-Cloud, France. mf.pichon@stcloud-huguenin.org | lld:pubmed |
| pubmed-article:15074470 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15074470 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15074470 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15074470 | lld:pubmed |
